ertugliflozin

 

Topic mentions per year

Topic mentions per year

2013-2017
0246820132017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Ertugliflozin (Steglatro™) is an orally active sodium glucose co-transporter type 2 inhibitor being developed by Merck and Pfizer… (More)
Is this relevant?
2018
2018
AIMS To assess ertugliflozin in patients with type 2 diabetes who are inadequately controlled by metformin and sitagliptin… (More)
  • table 1
  • figure 1
  • figure 2
Is this relevant?
2018
2018
AIM We evaluated the efficacy and safety of ertugliflozin, an SGLT2 inhibitor, in type 2 diabetes mellitus (T2DM) inadequately… (More)
Is this relevant?
2018
2018
INTRODUCTION Ertugliflozin is a sodium-glucose cotransporter 2 inhibitor in development for type 2 diabetes mellitus (T2DM). The… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
Is this relevant?
2018
2018
INTRODUCTION Ertugliflozin is an oral sodium-glucose cotransporter 2 inhibitor that is being developed to treat type 2 diabetes… (More)
Is this relevant?
2017
2017
AIMS To conduct a phase III study to evaluate the efficacy and safety of ertugliflozin monotherapy in people with type 2 diabetes… (More)
Is this relevant?
Review
2017
Review
2017
1. Several sodium-glucose cotransporter-2 (SGLT-2) inhibitors are in clinical use for the management of type 2 diabetes. The… (More)
Is this relevant?
2015
2015
This study compared the blood pressure-lowering effect of ertugliflozin (1, 5, 25 mg), hydrochlorothiazide (HCTZ; 12.5 mg) and… (More)
  • figure 1
Is this relevant?
2015
2015
AIM To investigate the efficacy and safety of ertugliflozin, in a phase II dose-ranging study, in patients with type 2 diabetes… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2013
2013
The disposition of ertugliflozin (PF-04971729), an orally active selective inhibitor of the sodium-dependent glucose… (More)
  • table 3
  • table 4
  • table 5
Is this relevant?